![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
G Battaglia, SY Yeh, E O'Hearn, ME Molliver, MJ Kuhar and EB De Souza
Neuroscience Branch, National Institute on Drug Abuse, Baltimore, Maryland.
This study examines the effects of repeated systemic administration (20 mg/kg s.c., twice daily for 4 days) of 3,4- methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on levels of brain monoamines, their metabolites and on the density of monoamine uptake sites in various regions of rat brain. Marked reductions (30-60%) in the concentration of 5- hydroxyindoleacetic acid were observed in cerebral cortex, hippocampus, striatum, hypothalamus and midbrain at 2 weeks after a 4-day treatment regimen of MDMA or MDA; less consistent reductions in serotonin (5-HT) content were observed in these brain regions. In addition, both MDMA and MDA caused comparable and substantial reductions (50-75%) in the density of [3H]paroxetine-labeled 5-HT uptake sites in all brain regions examined. In contrast, neither MDMA nor MDA caused any widespread or long-term changes in the content of the catecholaminergic markers (i.e., norepinephrine, dopamine, 3,4 dihydroxyphenylacetic acid and homovanillic acid) or in the number of [3H]mazindol-labeled norepinephrine or dopamine uptake sites in the brain regions examined. These data demonstrate that MDMA and MDA cause long-lasting neurotoxic effects with respect to both the functional and structural integrity of serotonergic neurons in brain. Furthermore, our measurement of reductions in the density of 5-HT uptake sites provides a means for quantification of the neurodegenerative effects of MDMA and MDA on presynaptic 5-HT terminals.
This article has been cited by other articles:
|
|
 |
|
  R. Carhart-Harris, D. Nutt, M Munafo, and S. Wilson Current and former ecstasy users report different sleep to matched controls: a web-based questionnaire study J Psychopharmacol, May 1, 2009; 23(3): 249 - 257. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Selvaraj, R. Hoshi, Z. Bhagwagar, N. V. Murthy, R. Hinz, P. Cowen, H. V. Curran, and P. Grasby Brain serotonin transporter binding in former users of MDMA ('ecstasy') The British Journal of Psychiatry, April 1, 2009; 194(4): 355 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Alves, T. Summavielle, C. J. Alves, J. Gomes-da-Silva, J. C. Barata, E. Fernandes, M. de Lourdes Bastos, M. A. Tavares, and F. Carvalho Monoamine Oxidase-B Mediates Ecstasy-Induced Neurotoxic Effects to Adolescent Rat Brain Mitochondria J. Neurosci., September 19, 2007; 27(38): 10203 - 10210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Reneman, M. M. L. de Win, W. van den Brink, J. Booij, and G. J. den Heeten Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects J Psychopharmacol, March 1, 2006; 20(2): 164 - 175. [Abstract] [PDF]
|
|
|
|
|
|
N. Easton and C. A. Marsden Ecstasy: Are animal data consistent between species and can they translate to humans? J Psychopharmacol, March 1, 2006; 20(2): 194 - 210. [Abstract] [PDF]
|
|
|
|
|
|
R. Thomasius, P. Zapletalova, K. Petersen, R. Buchert, B. Andresen, L. Wartberg, B. Nebeling, and A. Schmoldt Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective J Psychopharmacol, March 1, 2006; 20(2): 211 - 225. [Abstract] [PDF]
|
|
|
|
|
|
J. Daumann, B. Till, T. Fischermann, M. Rezk, and E. Gouzoulis-Mayfrank Intensity dependence of auditory evoked dipole source activity in polydrug ecstasy users: evidence from an 18 months longitudinal study J Psychopharmacol, March 1, 2006; 20(2): 236 - 244. [Abstract] [PDF]
|
|
|
|
|
|
E. J. Bull, V. Porkess, M. Rigby, P. H. Hutson, and K. C. F. Fone Pre-treatment with 3,4-methylenedioxymethamphetamine (MDMA) causes long-lasting changes in 5-HT2A receptor-mediated glucose utilization in the rat brain J Psychopharmacol, March 1, 2006; 20(2): 272 - 280. [Abstract] [PDF]
|
|
|
|
|
|
J. M. Breier, M. G. Bankson, and B. K. Yamamoto L-Tyrosine Contributes to (+)-3,4-Methylenedioxymethamphetamine-Induced Serotonin Depletions J. Neurosci., January 4, 2006; 26(1): 290 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wang, M. H. Baumann, H. Xu, M. Morales, and R. B. Rothman ({+/-})-3,4-Methylenedioxymethamphetamine Administration to Rats Does Not Decrease Levels of the Serotonin Transporter Protein or Alter Its Distribution between Endosomes and the Plasma Membrane J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1002 - 1012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Pifl, G. Nagy, S. Berenyi, A. Kattinger, H. Reither, and S. Antus Pharmacological Characterization of Ecstasy Synthesis Byproducts with Recombinant Human Monoamine Transporters J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 346 - 354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Darvesh, B. K. Yamamoto, and G. A. Gudelsky Evidence for the Involvement of Nitric Oxide in 3,4-Methylenedioxymethamphetamine-Induced Serotonin Depletion in the Rat Brain J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 694 - 701. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Greenhill, S. Pliszka, M. K. Dulcan, W. Bernet, V. Arnold, J. Beitchman, R. S. Benson, O. Bukstein, J. Kinlan, J. McClellan, et al. Practice Parameter for the Use of Stimulant Medications in the Treatment of Children, Adolescents, and Adults Focus, October 1, 2004; 2(4): 642 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Jones, S. S. Lau, and T. J. Monks Thioether Metabolites of 3,4-Methylenedioxyamphetamine and 3,4-Methylenedioxymethamphetamine Inhibit Human Serotonin Transporter (hSERT) Function and Simultaneously Stimulate Dopamine Uptake into hSERT-Expressing SK-N-MC Cells J. Pharmacol. Exp. Ther., October 1, 2004; 311(1): 298 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Baucum II, K. S. Rau, E. L. Riddle, G. R. Hanson, and A. E. Fleckenstein Methamphetamine Increases Dopamine Transporter Higher Molecular Weight Complex Formation via a Dopamine- and Hyperthermia-Associated Mechanism J. Neurosci., March 31, 2004; 24(13): 3436 - 3443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. D'Souza, Y. Zhang, F. Garcia, G. Battaglia, and L. D. Van de Kar Fluoxetine-induced changes in body weight and 5-HT1A receptor-mediated hormone secretion in rats on a tryptophan-deficient diet Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2004; 286(2): R390 - R397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Verheyden, R. Maidment, and H. V. Curran Quitting Ecstasy: An Investigation of Why People Stop Taking the Drug and Their Subsequent Mental Health J Psychopharmacol, December 1, 2003; 17(4): 371 - 378. [Abstract] [PDF]
|
|
|
|
 |
|
 A. R. Green, A. O. Mechan, J. M. Elliott, E. O'Shea, and M. I. Colado The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") Pharmacol. Rev., September 1, 2003; 55(3): 463 - 508. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Buchert, R. Thomasius, B. Nebeling, K. Petersen, J. Obrocki, L. Jenicke, F. Wilke, L. Wartberg, P. Zapletalova, and M. Clausen Long-Term Effects of "Ecstasy" Use on Serotonin Transporters of the Brain Investigated by PET J. Nucl. Med., March 1, 2003; 44(3): 375 - 384. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Badon, A. Hicks, K. Lord, B. A. Ogden, S. Meleg-Smith, and K. J. Varner Changes in Cardiovascular Responsiveness and Cardiotoxicity Elicited during Binge Administration of Ecstasy J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 898 - 907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Darvesh, M. Shankaran, and G. A. Gudelsky 3,4-Methylenedioxymethamphetamine Produces Glycogenolysis and Increases the Extracellular Concentration of Glucose in the Rat Brain J. Pharmacol. Exp. Ther., April 1, 2002; 301(1): 138 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Reneman, C. B. L. M. Majoie, H. Flick, and G. J. den Heeten Reduced N-Acetylaspartate Levels in the Frontal Cortex of 3,4-Methylenedioxymethamphetamine (Ecstasy) Users: Preliminary Results AJNR Am. J. Neuroradiol., February 1, 2002; 23(2): 231 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Reneman, J. Lavalaye, B. Schmand, F. A. de Wolff, W. van den Brink, G. J. den Heeten, and J. Booij Cortical Serotonin Transporter Density and Verbal Memory in Individuals Who Stopped Using 3,4-Methylenedioxymethamphetamine (MDMA or "Ecstasy"): Preliminary Findings Arch Gen Psychiatry, October 1, 2001; 58(10): 901 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Reneman, C. B. L. M. Majoie, J. B. A. Habraken, and G. J. den Heeten Effects of Ecstasy (MDMA) on the Brain in Abstinent Users: Initial Observations with Diffusion and Perfusion MR Imaging Radiology, September 1, 2001; 220(3): 611 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. W. Broening, L. L. Morford, S. L. Inman-Wood, M. Fukumura, and C. V. Vorhees 3,4-Methylenedioxymethamphetamine (Ecstasy)-Induced Learning and Memory Impairments Depend on the Age of Exposure during Early Development J. Neurosci., May 1, 2001; 21(9): 3228 - 3235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Gouzoulis-Mayfrank, J. Daumann, F. Tuchtenhagen, S. Pelz, S. Becker, H.-J. Kunert, B. Fimm, and H. Sass Impaired cognitive performance in drug free users of recreational ecstasy (MDMA) J. Neurol. Neurosurg. Psychiatry, June 1, 2000; 68(6): 719 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Hatzidimitriou, U. D. McCann, and G. A. Ricaurte Altered Serotonin Innervation Patterns in the Forebrain of Monkeys Treated with (±)3,4-Methylenedioxymethamphetamine Seven Years Previously: Factors Influencing Abnormal Recovery J. Neurosci., June 15, 1999; 19(12): 5096 - 5107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Aguirre, M. Barrionuevo, B. Lasheras, and J. Del Río The Role of Dopaminergic Systems in the Perinatal Sensitivity to 3,4-Methylenedioxymethamphetamine-Induced Neurotoxicity in Rats J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1159 - 1165. [Abstract] [Full Text]
|
|
|
|
|
|
T. M. Cabrera-Vera and G. Battaglia Prenatal Exposure to Fluoxetine (Prozac) Produces Site-Specific and Age-Dependent Alterations in Brain Serotonin Transporters in Rat Progeny: Evidence from Autoradiographic Studies J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1474 - 1481. [Abstract] [Full Text]
|
|
|
|
|
|
L. D. V. d. Kar, Q. Li, T. M. Cabrera, M. S. Brownfield, and G. Battaglia Alterations in 8-Hydroxy-2-(dipropylamino)tetralin-Induced Neuroendocrine Responses after 5,7-Dihydroxytryptamine-Induced Denervation of Serotonergic Neurons J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 256 - 262. [Abstract] [Full Text]
|
|
|
|
 |
|
 U. D. McCann, K. A. Lowe, and G. A. Ricaurte REVIEW {blacksquare} : Long-lasting Effects of Recreational Drugs of Abuse on the Central Nervous System Neuroscientist, November 1, 1997; 3(6): 399 - 411. [Abstract] [PDF]
|
|
|
|
|
|
T. M. Cabrera-Vera, F. Garcia, W. Pinto, and G. Battaglia Effect of Prenatal Fluoxetine (Prozac) Exposure on Brain Serotonin Neurons in Prepubescent and Adult Male Rat Offspring J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 138 - 145. [Abstract] [Full Text]
|
|
|
|
|
|
L. H. Price, G. A. Ricaurte, J. H. Krystal, and G. R. Heninger Neuroendocrine and Mood Responses to Intravenous L-Tryptophan in 3,4-Methylenedioxymethamphetamine (MDMA) Users: Preliminary Observations Arch Gen Psychiatry, January 1, 1989; 46(1): 20 - 22. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Verebey, J. Alrazi, and J. H. Jaffe The Complications of 'Ecstasy' (MDMA) JAMA, March 18, 1988; 259(11): 1649 - 1650. [Abstract] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
